Why the study?
Is platelet aggregability altered in subjects with Hyperapobetalipoproteinemia compared to controls?
Is platelet aggregability altered in subjects with Hyperapobetalipoproteinemia compared to controls?
Unlike other dyslipidemias, hyperapobetalipoproteinemia does not appear to be associated with abnormal platelet function or aggregability, suggesting other mechanisms drive the associated premature coronary disease.
Answers are grounded in this paper and cite their sources.
No platelet dysfunction seen in hyperapobetalipoproteinemia; leaves open alternative mechanisms for its premature CAD risk.
Hyperapobetalipoproteinemia (HyperapoB) is a lipid disorder characterized by premature coronary disease, although the mechanisms have not been elucidated. Because abnormalities in platelet function may represent an enhanced susceptibility to coronary thrombosis, the aggregability of platelets was examined in hyperapoB subjects. Compared to controls, there were no significant differences in either platelet lipid composition or in aggregation to epinephrine, ADP, or collagen. In contrast to other dyslipidemias, platelet function does not appear to be abnormal in this well defined lipid disorder.
No takes yet. Share an insight, caveat, or question.
Miller et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: